Is dipyridamole useful in improving left ventricular systolic and diastolic function in patients with coronary slow flow?

Süner, Arif; Çetın, Mustafa

doi:10.1111/echo.13290

Cited by 9 publications

(10 citation statements)

References 30 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They showed that microvascular dysfunction partially normalizes after intracoronary infusion of dipyridamole. Similarly, Suner and Cetin 29) reported DD to improve in patients with CSFP treated with dipyridamole for 2 months.…”

Section: Discussionmentioning

confidence: 79%

Evolution of Diastolic Dysfunction in Patients with Coronary Slow Flow Phenomenon and Acute Non-ST Segment Elevation Myocardial Infarction

Zayat

Abdelaziz

Yousry

et al. 2021

J Cardiovasc Imaging

View full text Add to dashboard Cite

BACKGROUND Diastolic function has been reported to be impaired in many patients with coronary slow flow phenomenon (CSFP). CSFP has broad spectrum of clinical presentations, including non-ST elevation myocardial infarction (NSTEMI). We sought to study the short-term evolution of diastolic function in CSFP patients presenting with NSTEMI. METHODS This study included 92 patients with CSFP and acute NSTEMI. Conventional echocardiography Doppler imaging and tissue Doppler echocardiography imaging were used to evaluate diastolic function during index NSTEMI and after 3 months. RESULTS Mean age of study patients was 45.7 ± 6.8 years. The prevalence of diastolic dysfunction (DD) at baseline was 69 patients (75%) and 28 patients (30.4%) at 3 months, p < 0.001. Various diastolic function indices showed significant improvement from baseline to 3 months follow-up. E/Em was 17.32 ± 3.41 at baseline compared to 12.41 ± 5.58 at 3 months, p = 0.039. Septal e′ velocity was 5.67 ± 4.56 cm/s at baseline compared to 7.78 ± 3.22 cm/s at 3 months, p = 0.023. Medications used were not significantly different between those with improved versus unimproved DD. CONCLUSIONS Diastolic function seems to improve over short-term follow-up in patients with CSFP presenting with NSTEMI. This could reflect a transient worsening during acute NSTEMI.

show abstract

Section: Discussionmentioning

confidence: 79%

Evolution of Diastolic Dysfunction in Patients with Coronary Slow Flow Phenomenon and Acute Non-ST Segment Elevation Myocardial Infarction

Zayat

Abdelaziz

Yousry

et al. 2021

J Cardiovasc Imaging

View full text Add to dashboard Cite

show abstract

“…These conclusions are of great interest. Indeed, as the same authors reported in the discussion section, different results had been obtained before by other research groups in the same kind of patients,[ 8 9 10 11 ] who found an impaired diastolic function in patients with CSF, assessed with conventional parameters and with 2D STE analysis. Particularly, Wang et al .…”

mentioning

confidence: 72%

“…These results seem to be in line with the findings reported by Sezgin et al . [ 10 ] and Suner and Cetin[ 11 ] who found a reduced LV diastolic function and a normal systolic function. Of course, Fallah et al .…”

mentioning

confidence: 99%

“…[ 1 ] provided some interesting hypotheses to explain the different results obtained by Wang et al . Indeed, while the statement that diastolic dysfunction was too subtle to be detected by 2D analysis seems to be weak, since that other authors[ 9 10 11 ] were able to assess it using conventional parameters that are less sensitive than strain analysis,[ 5 ] and the relevance of systolic function influence on the diastolic parameters seems not to be confirmed in the previous studies,[ 10 11 ] the possibility of an underestimation of the confounding role of comorbidities such as diabetes and hypertension in the other reports cannot be excluded.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Left Atrial Function and Coronary Slow Flow: Is There Diastolic Dysfunction or Not?

Longobardo

2018

J Cardiovasc Echography

View full text Add to dashboard Cite

“…Currently, the treatments for CSF mainly include enhancement of microcirculation, protection of the vascular endothelium, anti-in ammatory treatment, and atherosclerosis inhibition. Drugs such as Statins [21], Nebivolol [22], Dipyridamole [23], Calcium channel blockers [24][25], Trimetazidine[26] and Nikodir [27] have been proven clinically effective for CSF. Coronary angiography(CAG) is the only effective way to diagnose CSF.…”

Section: Introductionmentioning

confidence: 99%

The Immediate And Long-Term Effects of Shexiang Tongxin Dropping Pill On Coronary Slow Flow: Study Protocol For A Randomized Double-Blind Placebo-Controlled Trial

Birong

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Coronary slow flow (CSF) is a phenomenon characterized by delayed contrast medium progression in angiography in the absence of obstructive coronary epicardial disease. However, there is currently no definite effective therapy. A small sample self-controlled study had suggested an immediate improvement in coronary slow blood flow by Shexiang Tongxin Dropping Pills (STDP). But high-quality evidences on drug dosage, medication cycle and long-term effects are still lacking while the mechanism of STDP remains unclear. Methods: This study is a randomized, double-blinded, and placebo-controlled clinical trial. A total of 64 CSF patients diagnosed by coronary angiography will be randomly allocated into the test group, using STDP, and the control group, using placebo. The main efficacy indicators for immediate effects include thrombolysis in myocardial infarction (TIMI) blood flow grading and corrected TIMI frame count. Long-term effects will be evaluated by the comparison of cardiac radionuclide score, and patient condition such as angina readmission rate and angina scale. The safety indicators include a routine complete blood count, liver and renal function test, cardiac markers (including TnI, CK-MB, Myo), NT-proBNP, coagulation function, 12-lead electrocardiogram, and echocardiography. All adverse events during the trial will be recorded. Moreover, endothelial factors (including ET-1, NO, eNOS, iNOS), inflammatory factors (including adropin, IL-6, IL-1, IL-18, TNF-α, Lp-PLA2, hs-CRP) will be observed. Blood stasis syndrome (including platelet activation factors such as CD62 and CD63, coagulation function and blood stasis syndrome score) will be evaluated.Trial registration: Chinese Clinical Trial Registry, ChiCTR2000035167. Registered on August 2, 2020. http://www.chictr.org.cn/showproj.aspx?proj=57349

show abstract

Is dipyridamole useful in improving left ventricular systolic and diastolic function in patients with coronary slow flow?

Abstract: Left ventricular systolic and diastolic function may be negatively affected by CSF. Dipyridamole may improve these functions, especially at the tissue level.

Cited by 9 publications

References 30 publications

Evolution of Diastolic Dysfunction in Patients with Coronary Slow Flow Phenomenon and Acute Non-ST Segment Elevation Myocardial Infarction

Evolution of Diastolic Dysfunction in Patients with Coronary Slow Flow Phenomenon and Acute Non-ST Segment Elevation Myocardial Infarction

Left Atrial Function and Coronary Slow Flow: Is There Diastolic Dysfunction or Not?

The Immediate And Long-Term Effects of Shexiang Tongxin Dropping Pill On Coronary Slow Flow: Study Protocol For A Randomized Double-Blind Placebo-Controlled Trial

Contact Info

Product

Resources

About